Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This strength is in addition to Mylan’s currently marketed 15 mg and 30 mg strengths of the product.

Temazepam Capsules are the generic version of Mallinckrodt’s Restoril®, a sleep aid, which had total U.S. sales of approximately $6 million for the 12 months ending March 31, according to IMS Health. Mylan has begun shipping this product.

Currently, Mylan has 118 ANDAs pending FDA approval representing $82.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, which represent $16.7 billion in annual brand sales, according to IMS Health.

Related posts:

1. Mental Health Risks with Popular Stop-Smoking Drugs The Food and Drug Administration (FDA) warns that patients taking...
2. FDA Grants Orphan Drug Designation To Oncophage For The Treatment Of Glioma Antigenics Inc. (NASDAQ: AGEN) announced that Oncophage® (vitespen) has been...
3. Wrinkles Be Gone: New Laser Treatment Approved for Home Use Laser treatment to remove wrinkles around the eyes could now...
4. FDA Issues Warning To Breast Pump Maker FDA last month sent a warning letter to a breast...
5. American Pain Society Endorses FDA Guideline For Medication Disposal Calling it “an important first step in attempting to reverse...

Related posts brought to you by Yet Another Related Posts Plugin.